Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
NCT: NCT05825417 · ACTIVE_NOT_RECRUITING
Brief Summary
The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH). The main question it aims to answer is whether structured changes in clinical therapy will be detectable using implanted regulatory approved devices. Participants will will be implanted with approved medical devices and will enter into a study of approved drugs to assess physiology, activity and patient reported quality-of-life (QoL) outcomes. Researchers will compare two therapeutic strategies in each individual patient to see if the study design provides enough evidence to personalise drug treatment plans.
Frequently Asked Questions
What is Pulmonary Hypertension: Intensification and Personalisation of Combination Rx?
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx is a clinical trial registered under NCT05825417. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT05825417?
The current status of NCT05825417 (Pulmonary Hypertension: Intensification and Personalisation of Combination Rx) is: ACTIVE_NOT_RECRUITING.
When did Pulmonary Hypertension: Intensification and Personalisation of Combination Rx start?
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx started on 2023-06-14.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.